{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:15:44Z","timestamp":1790158544871,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":3297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jpain.2014.05.008","type":"journal-article","created":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T12:00:15Z","timestamp":1402315215000},"page":"907-914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Soluble Epoxide Hydrolase Inhibition Is Antinociceptive in a Mouse Model of Diabetic Neuropathy"],"prefix":"10.1016","volume":"15","author":[{"given":"Karen","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Inceoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2014.05.008_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jpain.2004.09.001","article-title":"Neuropathic pain symptoms relative to overall pain rating","volume":"5","author":"Backonja","year":"2004","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2014.05.008_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s002130000569","article-title":"Conditioned place preference: What does it add to our preclinical understanding of drug reward?","volume":"153","author":"Bardo","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpain.2014.05.008_bib3","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.2174\/1381612054865000","article-title":"Antiepileptics and the treatment of neuropathic pain: Evidence from animal models","volume":"11","author":"Blackburn-Munro","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jpain.2014.05.008_bib4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"Diabetic neuropathies: A statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jpain.2014.05.008_bib5","series-title":"The Neuropharmacological Basis of Reward","first-page":"264","article-title":"Conditioned place preference as a measure of drug reward","author":"Carr","year":"1989"},{"key":"10.1016\/j.jpain.2014.05.008_bib6","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/0024-3205(83)90165-0","article-title":"Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections","volume":"33","author":"Carr","year":"1983","journal-title":"Life Sci"},{"key":"10.1016\/j.jpain.2014.05.008_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nn.2497","article-title":"Opioids activate brain analgesic circuits through cytochrome P450\/epoxygenase signaling","volume":"13","author":"Conroy","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpain.2014.05.008_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2014.05.008_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/431980","article-title":"The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy","volume":"2009","author":"Davidson","year":"2009","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.jpain.2014.05.008_bib10","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jpain.2011.01.010","article-title":"Conditioned place preference reveals tonic pain in an animal model of central pain","volume":"12","author":"Davoody","year":"2011","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2014.05.008_bib11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2014.05.008_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.05.005","article-title":"Diabetic neuropathy: Mechanisms to management","volume":"120","author":"Edwards","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpain.2014.05.008_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/vaa.12030","article-title":"Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis","volume":"40","author":"Guedes","year":"2013","journal-title":"Vet Anaesth Analg"},{"key":"10.1016\/j.jpain.2014.05.008_bib14","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1021\/jm070270t","article-title":"Orally bioavailable potent soluble epoxide hydrolase inhibitors","volume":"50","author":"Hwang","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2014.05.008_bib15","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.lfs.2006.07.031","article-title":"Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain","volume":"79","author":"Inceoglu","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.jpain.2014.05.008_bib16","doi-asserted-by":"crossref","first-page":"18901","DOI":"10.1073\/pnas.0809765105","article-title":"Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways","volume":"105","author":"Inceoglu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpain.2014.05.008_bib17","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nn.2407","article-title":"Unmasking the tonic-aversive state in neuropathic pain","volume":"12","author":"King","year":"2009","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpain.2014.05.008_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuroscience.2008.02.031","article-title":"Pharmacological characterization and gene expression profiling of an L5\/L6 spinal nerve ligation model for neuropathic pain in mice","volume":"153","author":"Kiso","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpain.2014.05.008_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1194\/jlr.M031914","article-title":"Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in\u00a0vitro and in\u00a0vivo","volume":"54","author":"Kundu","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jpain.2014.05.008_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1744-8069-6-83","article-title":"Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain","volume":"6","author":"Kusunose","year":"2010","journal-title":"Mol Pain"},{"key":"10.1016\/j.jpain.2014.05.008_bib21","first-page":"895","article-title":"Central sensitization: A generator of pain hypersensitivity by central neural plasticity","volume":"10","author":"Latremoliere","year":"2009","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.jpain.2014.05.008_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ejps.2012.12.013","article-title":"Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models","volume":"48","author":"Liu","year":"2013","journal-title":"Eur J Pharmaceutical Sci"},{"key":"10.1016\/j.jpain.2014.05.008_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1476-5381.2008.00009.x","article-title":"Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation","volume":"156","author":"Liu","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpain.2014.05.008_bib24","doi-asserted-by":"crossref","first-page":"E375","DOI":"10.1152\/ajpendo.00131.2009","article-title":"Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase","volume":"297","author":"Luria","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jpain.2014.05.008_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrn2606","article-title":"Animal models of pain: Progress and challenges","volume":"10","author":"Mogil","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jpain.2014.05.008_bib26","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1194\/jlr.M006007","article-title":"Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids","volume":"51","author":"Morisseau","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jpain.2014.05.008_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0006-8993(82)91123-4","article-title":"Drug reinforcement studied by the use of place conditioning in rat","volume":"243","author":"Mucha","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/j.jpain.2014.05.008_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1213\/ANE.0b013e31826e1007","article-title":"Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: The effects of gabapentin, ketorolac, and etanercept","volume":"116","author":"Park","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpain.2014.05.008_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpain.2014.05.008_bib30","doi-asserted-by":"crossref","first-page":"40504","DOI":"10.1074\/jbc.M008106200","article-title":"Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation","volume":"275","author":"Sinal","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpain.2014.05.008_bib31","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/0091-3057(86)90514-9","article-title":"Brain areas involved in production of morphine-induced locomotor hyperactivity of the C57B1\/6J mouse","volume":"24","author":"Stevens","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpain.2014.05.008_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0304-3959(94)90130-9","article-title":"Conditioned place preference paradigm: A novel approach for analgesic drug assessment against chronic pain","volume":"58","author":"Sufka","year":"1994","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2014.05.008_bib33","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.pain.2011.04.028","article-title":"Translational challenges and analgesic screening assays","volume":"152","author":"Sufka","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2014.05.008_bib34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1124\/jpet.108.136739","article-title":"Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray","volume":"326","author":"Terashvili","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpain.2014.05.008_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2009.11.016","article-title":"Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice","volume":"628","author":"Tomi\u0107","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpain.2014.05.008_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1369-1600.2007.00070.x","article-title":"Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade","volume":"12","author":"Tzschentke","year":"2007","journal-title":"Addict Biol"},{"key":"10.1016\/j.jpain.2014.05.008_bib37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FJC.0b013e318185fa3c","article-title":"Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model","volume":"52","author":"Ulu","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jpain.2014.05.008_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejphar.2012.12.015","article-title":"Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models","volume":"700","author":"Wagner","year":"2013","journal-title":"Eur J Pharmacol"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152659001400741X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152659001400741X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:57:10Z","timestamp":1761508630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152659001400741X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S152659001400741X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2014.05.008","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble Epoxide Hydrolase Inhibition Is Antinociceptive in a Mouse Model of Diabetic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2014.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Pain Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}